ライフサイエンスコーパス: dengue

1 and seasonal diseases such as influenza and dengue.

2 le host-directed treatment for patients with dengue.

3 ents and symptomatic virologically confirmed dengue.

4 ressed replication of the related flavivirus dengue.

5 s a self-limiting febrile illness similar to dengue.

6 l role of chymase in vascular leakage during dengue.

7 and 89.2% (82.4 - 93.3) against hospitalized dengue.

8 not show antiviral efficacy in patients with dengue.

9 Aedes-borne diseases, such as dengue and chikungunya, are responsible for more than 50

10 Acute febrile illnesses such as dengue and chikungunya, which pose high burdens of disea

11 n shown to participate in immune response in dengue and HIV.

12 Dengue and influenza-like illness (ILI) are two of the l

13 l activity against diverse viruses including dengue and influenza.

14 Recent years have seen rising incidence of dengue and large outbreaks of Zika and chikungunya, whic

15 nown etiologies during seasonal outbreaks of dengue and other arborviruses.

16 promising targets for drug discovery against dengue and other flaviviruses is the viral serine protea

17 SARS-CoV-2 serology-status in patients with dengue and performed in-silico protein structural analys

18 V) up to Month 36 in part 1, and symptomatic dengue and serious adverse events (SAEs) up to Month 36

19 Dengue and West Nile virus are rapidly spreading global

20 ctam electrophilic warheads as inhibitors of dengue and West Nile virus NS2B-NS3 protease.

21 Lyn as a critical component for secretion of Dengue and Zika infectious particles and their correspon

22 serotype poses challenges to development of dengue and Zika vaccines.

23 We found that WNV, dengue and Zika virus capsids interact with a conserved

24 aegypti venom allergen-1 (AaVA-1), promotes dengue and Zika virus transmission by activating autopha

25 Previous flavivirus (dengue and Zika viruses) studies showed largely spherica

26 le for acyl-carnitines in the replication of dengue and Zika viruses.

27 e insects transmit diseases such as malaria, dengue and Zika; therefore, control methods that bias th

28 e, 90.4% (82.6 to 94.7) against hospitalised dengue, and 85.9% (31.9 to 97.1) against dengue haemorrh

29 or all-in-one molecular diagnostics of zika, dengue, and chikungunya virus from human serum.

30 es transmitted by mosquitoes including zika, dengue, and chikungunya, are becoming a serious problem

31 baseline serostatus, serotype, hospitalised dengue, and severe dengue) in the first 17 months.

32 f several flaviviruses, including West Nile, dengue, and yellow fever viruses, is capable of inducing

33 phagy constituents are proviral (poliovirus, dengue, and Zika), we developed a panel of knockouts (KO

34 review recent discoveries of gene sets, anti-dengue antibody properties, and inflammatory markers wit

35 inically usable biomarkers to predict severe dengue are needed.

36 -transmitted diseases, including malaria and dengue, are a major threat to human health around the gl

37 with varying severity of COVID-19 and acute dengue at different time points of illness.

38 ve, rapid, and field deployable diagnosis of dengue at the early stage (within 5 days of the onset of

39 amples obtained from patients diagnosed with dengue before September 2019, SARS-CoV-2 serology target

40 tection of non-structural 1 (NS1) protein, a dengue biomarker.

41 der long-term febrile surveillance to detect dengue by serotype-specific RT-PCR.

42 , viral load, and disease severity among 133 dengue cases in a Nicaraguan pediatric cohort study.

43 chanism of antibody-dependent enhancement in dengue cases.

44 Based upon human dengue challenge studies, one of these vaccines promises

45 % accuracy for the detection of Zika, Ebola, dengue, chikungunya and yellow fever viruses in plasma s

46 he main vector of arboviral diseases such as dengue, chikungunya and Zika.

47 Importantly, in two independent human dengue cohorts, tryptase levels correlated with the grad

48 similar between dengue-infected and HIV plus dengue-coinfected patients, plasma levels of the platele

49 the acute phase of disease in DHF or Severe dengue, defined by either the 1997 or 2009 WHO diagnosis

50 d arbovirus infection were tested for CHIKV, dengue (DENV) and Zika virus (ZIKV).

51 e spatial arrangement of ED3 clusters on the dengue (DENV) viral surface.

52 gainst rapidly mutating RNA viruses, such as dengue (DENV), yet how viral diversity affect T cell res

53 dy, we tested pools of epitopes derived from dengue (DENV), Zika (ZIKV), Japanese encephalitis (JEV),

54 hymase levels are associated with DHF/Severe dengue disease in hospitalized pediatric patients.

55 ation that prior ZIKV infection can modulate dengue disease severity like a DENV serotype poses chall

56 Such a scenario may lead to severe dengue disease.

57 immunosuppressive IL-10 in both COVID-19 and dengue during early illness are indicators of an altered

58 population susceptibility and climate drives dengue dynamics in a nonlinear and complex, yet predicta

59 ied drivers and their interactive effects on dengue dynamics in San Juan, Puerto Rico.

60 the detection of human papilloma, vaccinia, dengue, Ebola, influenza A, human immunodeficiency, and

61 three years in children and adults living in dengue endemic countries, with limited contribution from

62 ing healthcare resources more effectively in dengue endemic countries.

63 chikungunya viruses in Recife, Pernambuco, a dengue-endemic area of Brazil.

64 03) in healthy children and adults living in dengue-endemic areas in Puerto Rico, Columbia, Singapore

65 ese findings confirm that children living in dengue-endemic countries receive intense early dengue ex

66 over a 48-month period in children living in dengue-endemic countries.

67 Dengue endemicity varies but comparative, multi-country

68 A plant-derived dengue envelope domain III (EDIII) protein was used as t

69 -like motifs, was constructed to display ten dengue envelope protein domain III (ED3)-targeting aptam

70 the HR2-domain of the spike-protein and the dengue envelope-protein.

71 ngue-endemic countries receive intense early dengue exposure, increasing risk of secondary infection,

72 vels remained unchanged in those with DHF or dengue fever (DF) during febrile and critical phases.

73 nfounded with other febrile illnesses (e.g., dengue fever and leptospirosis) and point-of-care testin

74 COVID-19 and dengue fever are difficult to distinguish given shared c

75 n 1 (NS1 DENV) is considered a biomarker for dengue fever in an early stage.

76 Dengue virus (DENV) infection causes dengue fever in humans, which can lead to thrombocytopen

77 mined in a discovery cohort of patients with dengue fever or dengue hemorrhagic fever (DHF) (n = 166)

78 of clinical symptoms, ranging from classical dengue fever to severe dengue hemorrhagic fever or dengu

79 ectrum of severity in humans from the milder dengue fever to severe disease, or dengue hemorrhagic fe

80 f infections which produced a higher risk of dengue fever upon secondary infection are: DEN1 followed

81 ety of viruses, e.g., SARS-CoV-2, influenza, dengue fever, hepatitis C virus, HIV, rotavirus and Zika

82 ographical sites in 13 countries to estimate dengue force of infection (FOI, the proportion of childr

83 rosurveys, the year-on-year estimates of the dengue force of infection from 1930 to 2017 revealed a s

84 Those without previous dengue had a higher risk of death (hazard ratio: 0.44; 9

85 a and multiorgan dysfunction in COVID-19 and dengue haemorrhagic fever (DHF) are two diseases that ca

86 sed dengue, and 85.9% (31.9 to 97.1) against dengue haemorrhagic fever.

87 very cohort of patients with dengue fever or dengue hemorrhagic fever (DHF) (n = 166) and controls (n

88 he milder dengue fever to severe disease, or dengue hemorrhagic fever (DHF).

89 anging from classical dengue fever to severe dengue hemorrhagic fever or dengue shock syndrome; howev

90 g a marked reduction in platelet counts, and dengue hemorrhagic fever.

91 Be observant of dengue-HLH due to its high mortality.

92 tives were to (1) determine the frequency of dengue-HLH in SD, (2) describe clinical features of deng

93 HLH in SD, (2) describe clinical features of dengue-HLH, (3) assess mortality rate in SD and dengue-H

94 gue-HLH, (3) assess mortality rate in SD and dengue-HLH, and (4) identify mortality-associated risk f

95 ing multiorgan failure at risk of developing dengue-HLH.

96 ho are falsely identified as seropositive by dengue IgG ELISA and then vaccinated might be at risk of

97 We aimed to evaluate the performance of a dengue IgG indirect ELISA in determining dengue seroprev

98 ers of clinical importance in the context of dengue illness.

99 les in hospitalized Thai children with acute dengue illness.

100 ve surveillance is performed to detect acute dengue illnesses, and annual blood testing identifies su

101 While the parameters contributing to dengue immunopathogenesis remain unclear, the collapse o

102 olerated and efficacious against symptomatic dengue in children regardless of serostatus before immun

103 We test NobBS on dengue in Puerto Rico and influenza-like illness (ILI) i

104 nostic tool for the serological detection of dengue in realistic applications.

105 s, serotype, hospitalised dengue, and severe dengue) in the first 17 months.

106 in mosquitoes in urban settings and decrease dengue incidence in humans.

107 ill over recent, state-of-the-art models for dengue incidence.

108 f vector-borne diseases, for example Zika or dengue, include using larvicide and/or adulticide, eithe

109 to identify whether warning signs of severe dengue, including hypovolemia and fluid accumulation, we

110 e of 1.0 log10 copies/mL, the odds of severe dengue increased approximately 50%, regardless of severi

111 Dengue induces a spectrum of severity in humans from the

112 and platelet activation were similar between dengue-infected and HIV plus dengue-coinfected patients,

113 looked for evidence of Zika, chikungunya, or dengue infection by viral RNA or specific IgM antibodies

114 Dengue infection induces a spectrum of clinical symptoms

115 ay for distinguishing positive from negative dengue infection samples is imperative for epidemic cont

116 , 55 [27%] had chikungunya, and two [1%] had dengue infection), whereas 50 (25%) had evidence of dual

117 stic assays to predict progression to severe dengue infection, which is a major global threat.

118 ion of the world's population is at risk for dengue infection.

119 with COVID-19, 1177 (50%) reported previous dengue infection.

120 ting of human cells eliciting <3% productive dengue infection.

121 a on dengue notifications do not capture all dengue infections and do not reflect the true intensity

122 Dengue is a global health problem requiring an effective

123 Dengue is a major public health concern in the tropical

124 Dengue is a serious global health concern especially in

125 Laboratory diagnosis of dengue is essential for providing appropriate supportive

126 cal illness and infectious epidemics such as Dengue is often fatal, our model demonstrates an afforda

127 Dengue is one of the most widespread vector-borne viral

128 While antibody-dependent enhancement of dengue is thought to be driven by viral load, this has n

129 Using the dengue lateral-flow rapid test we detected 12 positive c

130 We evaluated dengue management options in an endemic setting that com

131 These findings raise the possibility that dengue might induce immunological protection against SAR

132 s failed to confer protection in symptomatic dengue mouse models using two non-mouse-adapted DENV2 st

133 A replication cohort of patients with dengue (n = 222) was used to confirm specific MICB assoc

134 found that 320 (10.7%) of 2996 children were dengue naive and 2676 (89.3%) were seropositive for prev

135 d efficacy of 67.0% (95% CI: 53.6 - 76.5) in dengue-naive and 89.2% (82.4 - 93.3) against hospitalize

136 isease, particularly for individuals who are dengue-naive and those younger than 9 years.

137 tical tool to differentiate dengue positive, dengue negative, and healthy subjects on the basis of th

138 Dengue non-structural protein 1 (NS1 DENV) is considered

139 National data on dengue notifications do not capture all dengue infection

140 rmal annealing of thin metal film, to detect dengue NS1 antigen, which appears as early as the onset

141 ) cells infected with Wolbachia only, either dengue or Zika virus only, and Wolbachia-infected Aag2 c

142 nfected Aag2 cells superinfected with either dengue or Zika virus.

143 ound effects of the current Central American dengue outbreak happening during the SARS-CoV-2 pandemic

144 portant but poorly understood contributor of dengue outbreaks.

145 Cumulative efficacy against dengue over ~27 months since first dose was 72.7% (95% C

146 PCSK9 plays a hitherto unrecognized role in dengue pathogenesis and that PCSK9 inhibitors could be a

147 Dengue pathogenesis is extremely complex.

148 While the majority of symptomatic dengue patients experience an acute febrile illness, 5-2

149 and longitudinally in hospitalized pediatric dengue patients in Sri Lanka.

150 mainstay of management for most symptomatic dengue patients remains careful observation and prompt b

151 roviding appropriate supportive treatment to dengue patients with febrile illness, which is difficult

152 Dengue patients with thrombocytopenia who were older or

153 Platelet transfusion is common in dengue patients with thrombocytopenia.

154 We analyzed patients from the Adult Dengue Platelet Study with laboratory-confirmed dengue w

155 yed as the statistical tool to differentiate dengue positive, dengue negative, and healthy subjects o

156 hymase is a candidate biomarker that may aid dengue prognosis.

157 motype of potent small-molecule non-peptidic dengue protease inhibitors derived from 4-benzyloxypheny

158 The activity against dengue protease was in general higher than against West

159 ases avoided for a decade despite continuous dengue reintroductions.

160 rast, multiple prior DENV infections reduced dengue risk.

161 mination and monitoring of pathogenic (Zika, Dengue, SARS-Cov-2 (inducer of COVID-19), human papillom

162 Globally, ~500 000 people with severe dengue (SD) require hospitalization yearly; ~12 500 (2.5

163 SARS-CoV-2, which can lead to false-positive dengue serology among COVID-19 patients and vice versa.

164 g to consider COVID-19 due to false-positive dengue serology can have serious implications.

165 To assess dengue serology-status, we used dengue-specific antibodi

166 1961 non-imputed FRNT results classified as dengue seronegative or seropositive, the ELISA (with a 0

167 f a dengue IgG indirect ELISA in determining dengue seroprevalence in a cohort of children in the Phi

168 The primary endpoint was dengue seroprevalence in the cohort, detected by ELISA,

169 of CYD-TDV results in essentially equivalent dengue serotype-specific NAb titers as the currently use

170 ed neutralizing antibody titers for the four dengue serotypes (DENV) up to Month 36 in part 1, and sy

171 ansmitted case studies, namely, outbreaks of dengue serotypes in Puerto Rico and a rapidly unfolding

172 ity was mediated by viral load for each of 3 dengue severity outcomes.

173 ition enzyme-linked immunosorbent assay) and dengue severity, categorized using 3 definitions.

174 viral load was significantly associated with dengue severity; for each increase of 1.0 log10 copies/m

175 fever to severe dengue hemorrhagic fever or dengue shock syndrome; however, the complexities of DENV

176 To assess dengue serology-status, we used dengue-specific antibodies by means of lateral-flow rapi

177 susceptibility, temperature and rainfall on dengue transmission empirically, our model improves fore

178 sent study thus aims to stratify malaria and dengue using Raman spectroscopy (RS).

179 tudy and eligible to participate in the mass dengue vaccination campaign were seropositive for previo

180 to be aged 9-14 years at the time of a mass dengue vaccination campaign.

181 he Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine (CYD-TDV, Dengvaxia) when administered on

182 unogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4-16 y

183 ee different dose schedules of a tetravalent dengue vaccine (TAK-003) over a 48-month period in child

184 y and immunogenicity of Takeda's tetravalent dengue vaccine candidate (TAK-003) in healthy children a

185 rial of Takeda's live-attenuated tetravalent dengue vaccine candidate (TAK-003).

186 warrants reevaluation of NS1 as a universal dengue vaccine candidate.

187 fection and provide a potential strategy for dengue vaccine design.

188 Takeda's dengue vaccine is under evaluation in an ongoing Phase 3

189 al need remains for an effective tetravalent dengue vaccine suitable for all age groups, regardless o

190 (WHO) testing guidance for the only licensed dengue vaccine, CYD-TDV; and preliminary results for in-

191 health problem requiring an effective, safe dengue vaccine.

192 ecific IgG responses elicited by a candidate dengue vaccine.

193 challenged the development and evaluation of dengue vaccines.

194 ness were tested for virologically confirmed dengue (VCD) by serotype-specific RT-PCR.

195 g that often shows cross-reactivity with the Dengue virus (DENV) and other flaviviruses.

196 are exquisitely required for replication of dengue virus (DENV) and other mosquito-borne flaviviruse

197 of global public health importance, such as dengue virus (DENV) and yellow fever virus (YFV), origin

198 minant target of neutralizing antibodies for dengue virus (DENV) and yellow fever virus (YFV).

199 Flaviviruses, including dengue virus (DENV) and Zika virus (ZIKV), rely heavily

200 Because dengue virus (DENV) and ZIKV co-circulate, understanding

201 Low preexisting anti-dengue virus (DENV) antibody levels are associated with

202 Dengue virus (DENV) can cause life-threatening disease c

203 ut the complex effects of age and sequential dengue virus (DENV) exposures on these correlations.

204 in the host immune response directed against dengue virus (DENV) has demonstrated the need to underst

205 antigenic glycoprotein for the detection of dengue virus (DENV) IgG antibodies.

206 cas, a major question that has arisen is how dengue virus (DENV) immunity impacts Zika virus infectio

207 Dengue virus (DENV) infection causes dengue fever in hum

208 Dengue virus (DENV) infection disrupts host innate immun

209 The increased prevalence of dengue virus (DENV) infection has had a significant soci

210 cell-associated viral reservoir during acute dengue virus (DENV) infection remains unclear.

211 Dengue virus (DENV) infection requires cholesterol as a

212 sma leakage are immune-pathologies of severe dengue virus (DENV) infection, but the mechanisms underl

213 ated with susceptibility to DHF in secondary dengue virus (DENV) infections (odds ratio [OR], 3.22; [

214 from patients during clinical influenza and dengue virus (DENV) infections.

215 Dengue virus (DENV) is a global health threat, causing r

216 nd inflammation in DENV infection.IMPORTANCE Dengue virus (DENV) is a mosquito-borne pathogen that th

217 Dengue virus (DENV) is a mosquito-borne virus that infec

218 Dengue virus (DENV) is responsible for the most prevalen

219 Preexisting immunity to Zika virus (ZIKV) or dengue virus (DENV) may alter the course of their infect

220 Dengue virus (DENV) NS5 RNA-dependent RNA polymerase (Rd

221 spite replicating in the cytoplasm, ZIKV and Dengue virus (DENV) polymerases, NS5 proteins, are predo

222 tralizing antibodies to distinguish ZIKV and dengue virus (DENV) responses, which we found were commo

223 The 4 antigenically distinct serotypes of dengue virus (DENV) share extensive homology with each o

224 Dengue virus (DENV) subdues cell membranes for its cellu

225 The rational design of dengue virus (DENV) vaccines requires a detailed underst

226 Dengue virus (DENV) was designated as a top 10 public he

227 ly related to other human pathogens, such as dengue virus (DENV)(1).

228 sting target sites for inhibition.IMPORTANCE Dengue virus (DENV), an important arthropod-transmitted

229 ral protein 5 (NS5) of Zika virus (ZIKV) and dengue virus (DENV), revealing two-pronged interactions

230 egree of sequence and structural homology to Dengue virus (DENV), the role of immunological cross-rea

231 es many medically important viruses, such as dengue virus (DENV), Zika virus (ZIKV), and yellow fever

232 oss the transcriptome following infection by dengue virus (DENV), Zika virus (ZIKV), West Nile virus

233 urified inactivated vaccine (ZPIV)(4-7) in a dengue virus (DENV)-experienced human elicited potent cr

234 squito borne viruses including flaviviruses (dengue virus (DENV; nine isolates analyzed), Japanese en

235 l Host & Microbe, Young et al. shed light on dengue virus 3-specific epitopes.

236 increases the competence of this species for dengue virus and chikungunya virus as well as Aedes albo

237 nge of different viral infections, including dengue virus and SARS-CoV, and consider ADE in the conte

238 gs support possible cross-reactivity between dengue virus and SARS-CoV-2, which can lead to false-pos

239 ng the last 70 years, including epidemics of dengue virus and West Nile virus, and the most recent ex

240 ctious particle production of HCV as well as dengue virus and Zika virus revealing a conserved requir

241 Structures of flavivirus (dengue virus and Zika virus) particles are known to near

242 Flaviviruses, including dengue virus and Zika virus, contain a single-stranded p

243 several human pathogenic viruses, including dengue virus and Zika virus.

244 erging mosquito-borne flavivirus, related to dengue virus and Zika virus.

245 Detection of dengue virus antibodies is important for understanding f

246 a long-term reduction in risk of symptomatic dengue virus disease in vaccinees.

247 ine-related serious adverse events or severe dengue virus disease were reported.

248 ains for safe and effective vaccines against dengue virus disease, particularly for individuals who a

249 Dengue virus elicits robust type-specific and cross-reac

250 ee chemically distinct vaccine components, a dengue virus Envelope protein Domain III (EDIII) subunit

251 y used with 5 clinical specimens of zika and dengue virus from real patients.

252 immunodeficiency virus, influenza virus, and dengue virus have evolved a multitude of mechanisms to e

253 d Raman scattering (SERS) based diagnosis of dengue virus in clinical blood samples collected from to

254 nal fluid, but postmortem analysis confirmed dengue virus in the brain by immunohistochemistry, in si

255 rature on this association in the context of dengue virus infection (DENV).

256 Dengue virus infection also induced cross-reactive MBC r

257 Previously it was shown that Dengue virus infection of the mosquito led to an in incr

258 tion campaign were seropositive for previous dengue virus infection.

259 2676 (89.3%) were seropositive for previous dengue virus infection.

260 Dengue virus is an emerging mosquito-borne flavivirus re

261 ent of vaccines against ZIKV and the related dengue virus is the induction of cross-reactive poorly n

262 ross-react with the E protein of the related dengue virus on account of the high level of similarity

263 bodies is important for understanding future dengue virus risk and for prevaccination screening.

264 116 also binds to and cross-neutralizes some dengue virus serotype 1 (DENV1) strains, with genotype-d

265 Based on dengue virus serotype-specific neutralizing antibody (NA

266 1%) among children with immunity to just one dengue virus serotype.

267 nterest in whether immune interactions among dengue virus serotypes 1 to 4 (DENV1 to -4) extend to th

268 However, other related flaviviruses, dengue virus serotypes 1 to 4 and the yellow fever 17D v

269 to provide protection against four different dengue virus stereotypes.

270 Norovirus submissions since May 2018 and for Dengue virus submissions since January 2019.

271 We used an agent-based model of dengue virus transmission calibrated to data from Iquito

272 ith a non-natural Wolbachia strain to reduce dengue virus transmission.

273 include Lassa pseudovirus, influenza virus, dengue virus type 2, herpes simplex virus 1, and nonenve

274 The leading dengue virus vaccine candidates in clinical testing are

275 antigens than E protein monomers.IMPORTANCE Dengue virus vaccine development is particularly challen

276 Previous respiratory syncytial virus and dengue virus vaccine studies revealed human clinical saf

277 Three targets, zika virus, dengue virus, and chikungunya virus, in human serum were

278 he within-host evolution of influenza virus, dengue virus, and cytomegalovirus.

279 o endemic mosquito-borne infections, such as dengue virus, both for routine management involving vect

280 accines against respiratory syncytial virus, dengue virus, SARS-CoV and Middle East respiratory syndr

281 at share a similar envelope protein, such as dengue virus, West Nile virus, and yellow fever virus.

282 Global arboviruses, including dengue virus, Zika virus, and chikungunya virus, have al

283 se during a subsequent exposure to wild-type dengue virus.

284 cal attributes of ADE disease exemplified by dengue viruses (DENV).

285 West Nile, Japanese encephalitis, Zika, and dengue viruses did not affect recall responses.

286 the infectivity of bovine viral diarrhea and dengue viruses in cellular models.

287 ble to suppress replication of West Nile and dengue viruses in infected cells in the micromolar range

288 Influenza and dengue viruses present a growing global threat to public

289 ntibody titres against ZIKV, but not against dengue viruses that circulated during the same period.

290 ELISA testing for dengue was positive in two additional subjects using env

291 Virologically confirmed dengue was recorded in 37 (2%) TAK-003 and 13 (7%) place

292 Emerging viruses like dengue, West Nile, chikungunya, and Zika can cause wides

293 gue Platelet Study with laboratory-confirmed dengue with <=20 000 platelets/muL and without persisten

294 levated plasma PCSK9 levels in patients with dengue with high viremia and increased severity of plasm

295 dependent of baseline serostatus in reducing dengue with some decline in efficacy during the second y

296 ti is the primary vector for transmission of Dengue, Zika and chikungunya viruses.

297 vasive mosquito vector for arboviruses (e.g. dengue, zika and yellow fever).

298 ses transmitted by Aedes mosquitoes, such as dengue, Zika, and chikungunya, have expanding ranges and

299 Aedes aegypti is the main vector of dengue, Zika, chikungunya, and yellow fever viruses.

300 ples of outbreaks, including those caused by dengue, Zika, yellow fever, West Nile, and chikungunya v